Responsiveness of FDG PET/CT to Treatment of Patients With Active Chronic Sarcoidosis
Responsiveness of FDG PET/CT to Treatment of Patients With Active Chronic Sarcoidosis
复制标题
DOI：
10.1097/rlu.0b013e31828731f5
复制
发表时间：
2013-07-01
影响因子：
10.6
通讯作者：
Obradovic, Vladimir B.
中科院分区：
文献类型：
--
作者：
Sobic-Saranovic, Dragana P.;Grozdic, Isidora T.;Obradovic, Vladimir B.
目的：本研究的目的是比较基线随访F-18-FDG PET/CT结果治疗后的活动性慢性结节病和相关的变化F-18-FDG PET/CT与临床status.Patients和方法的变化：样本包括66例慢性结节病和活动性炎症的证据，基线F-18-FDG PET/CT，他们接受治疗。在这66名患者中，30名患者在12（5）个月后返回接受随访F-18-FDG PET/CT，以评价治疗反应。他们还被要求指出临床状态的变化。结果：随访时SUVmax较基线F-18-FDG PET/CT显著降低（8.46 [3.52] vs 4.90 [0.96]; P = 0.006），主要发生在纵隔。9例患者的炎症活动消失，12例患者的炎症活动减少，9例患者的炎症活动增加，相应的SUVmax变化分别为-80%，-41%和+54%。F-18-FDG PET/CT的变化与患者自我感觉的临床症状变化一致（P = 0.019）。随访时的血管紧张素转换酶与基线相比无显著差异（49.80 [19.25] vs 46.35 [25.58]，P = 0.522）。有没有差异的患者的基线特征，没有返回follow-up.Conclusions：F-18-FDG PET/CT是能够检测临床有意义的变化的幅度和程度的炎症活动的患者接受治疗的活动性慢性结节病。因此，F-18-FDG PET/CT是监测这些患者治疗反应的临床评价的有价值的辅助手段。
Purpose: This study aimed to compare baseline to follow-up F-18-FDG PET/CT findings after treatment for active chronic sarcoidosis and to correlate changes on F-18-FDG PET/CT with changes in clinical status.Patients and Methods: The sample included 66 patients with chronic sarcoidosis and evidence of active inflammation on baseline F-18-FDG PET/CT for which they received therapy. Of these 66 patients, 30 returned for the follow-up F-18-FDG PET/CT after 12 (5) months to evaluate response to treatment. They were also asked to indicate changes in clinical status. Baseline characteristics of patients who did and did not return for the follow-up were compared to assess selection bias.Results: SUVmax was significantly decreased at the follow-up compared with baseline F-18-FDG PET/CT (8.46 [3.52] vs 4.90 [0.96]; P = 0.006), primarily in the mediastinum. Inflammatory activity appeared absent in 9 patients, decreased in 12 patients, and increased in 9 patients, with the corresponding changes in SUVmax of -80%, -41%, and +54%, respectively. The changes on F-18-FDG PET/CT were in agreement with self-perceived changes in clinical symptoms (P = 0.019). The angiotensin-converting enzyme at the follow-up was not significantly different from baseline (49.80 [19.25] vs 46.35 [25.58], P = 0.522). There was no difference in baseline characteristics of patients who did and did not return for the follow-up.Conclusions: F-18-FDG PET/CT is able to detect clinically meaningful changes in magnitude and extent of inflammatory activity in patients receiving treatment for active chronic sarcoidosis. Thus, F-18-FDG PET/CT is a valuable adjunct to clinical evaluation for monitoring the response to treatment in these patients.